Association of blood levels of marine omega-3 fatty acids with coronary calcification and calcium density in Japanese men
Authors:
- for the SESSA Research GroupFGfor the SESSA Research Group
- Akira SekikawaAkira Sekikawa
- Takashi HisamatsuTHTakashi Hisamatsu
- Akira FujiyoshiAFAkira Fujiyoshi
- Hiroshi MaegawaHMHiroshi Maegawa
- 26 July 2018
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Nutrition
- Vol. 73 (5) , 783-792
Abstract
Clinical trials of eicosapentaenoic acid (EPA) among high-risk groups in Japan in which consumption of mairne-omega-3 fatty acids (OM3) is much higher than other countries showed slower progression of coronary atherosclerosis. We aimed to determine the cross-sectional associations of coronary artery calcification (CAC) and calcium density with OM3, EPA, and docosahexaenoic acid (DHA), two principal OM3, in the general population in Japan. The Shiga Epidemiological Study of Subclinical Atherosclerosis examined a population-based sample of 1074 men aged 40–79 in 2006–08 for computed tomography-measured CAC score (CCS), a well-established biomarker of coronary atherosclerosis, CAC density score (CDS), a potential marker of plaque stabilization, serum levels of OM3, and risk factors. Prevalence of CCS > 0, ≥ 100, and ≥ 300 was 65.8%, 25.9%, and 12.9%, respectively; the mean (SD) OM3, EPA, and DHA were 10.1% (3.2), 3.2% (1.7), and 5.9% (1.6), respectively. Odds ratios (95% CI, p-value) of CCS 0, 100, and 300 in ordinal logistic regression associated with 1 SD increase of OM3, EPA, and DHA were 0.91 (0.81–1.03, p = 0.12), 0.99 (0.88–1.11, p = 0.87) and 0.84 (0.74–0.94, p = < 0.01), respectively. The inverse association of DHA with CCS remained significant in multivariate-adjusted model: odds ratio of 0.87 (0.77–0.99, p = 0.03). Blood levels of OM3, EPA, or DHA did not have any significant associations with CDS. DHA but not EPA had a significant inverse association with coronary atherosclerosis in the general population with high levels of OM3. Future trials are warranted comparing the effect of high-dose DHA and EPA on atherosclerosis and cardiovascular outcomes.Keywords
Funding Information
- U.S. Department of Health & Human Services | National Institutes of Health (R01 HL068200, RF1AG051615)
- Ministry of Education, Culture, Sports, Science, and Technology ((B) 21790579, (B) 26293140, (A) 23249036, (A) 15H02528, (A) 13307016, (A) 17209023, (A) 25253046)
- MEXT | National Institutes of Natural Sciences ((A) 21249043)
- GlaxoSmithKline (no number)
This publication has 50 references indexed in Scilit:
- n–3 Fatty Acids and Cardiovascular Outcomes in Patients with DysglycemiaNew England Journal of Medicine, 2012
- (n-3) Fatty Acids and Cardiovascular Health: Are Effects of EPA and DHA Shared or Complementary?The Journal of Nutrition, 2012
- Differential Association of Docosahexaenoic and Eicosapentaenoic Acids With Carotid Intima-Media ThicknessStroke, 2011
- Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trialBMJ, 2010
- n–3 Fatty Acids and Cardiovascular Events after Myocardial InfarctionNew England Journal of Medicine, 2010
- Revised Equations for Estimated GFR From Serum Creatinine in JapanAmerican Journal of Kidney Diseases, 2009
- Cardiovascular Disease and Risk Factors in AsiaCirculation, 2008
- Marine-Derived n-3 Fatty Acids and Atherosclerosis in Japanese, Japanese-American, and White MenJACC, 2008
- Less Subclinical Atherosclerosis in Japanese Men in Japan than in White Men in the United States in the Post-World War II Birth CohortAmerican Journal of Epidemiology, 2007
- Fish Intake, Contaminants, and Human HealthJAMA, 2006